OPTIMUS PRIME: Safety and Feasibility of OPTune GIO® Integrated With MRI-gUided Laser Ablation Surgery and Pembrolizumab for Recurrent GlIoblastoMa, A randomizEd Trial

This study (called OPTIMUS PRIME) is testing a combination of three treatments for people with recurring glioblastoma (a serious brain cancer that has come back): laser surgery to destroy the tumor from the inside, a device called Optune GIO® (which uses electric fields to kill cancer cells), and the immunotherapy drug pembrolizumab. **You may be eligible if...** - You are 18 or older with confirmed recurrent or progressive glioblastoma (Grade IV brain cancer) - Your tumor recurrence is clearly visible on MRI - You have a reasonable functional status (Karnofsky score ≥ 60%) - You are a candidate for the laser surgery, Optune device, and pembrolizumab based on your doctor's assessment - Your blood counts, liver, and kidneys are functioning adequately **You may NOT be eligible if...** - You have previously received anti-angiogenic drugs like bevacizumab (with rare exceptions) - You have received prior anti-PD-1 or PD-L1 immunotherapy - You have active autoimmune disease - You are pregnant or breastfeeding - You have a device incompatible with the Optune therapy Talk to your doctor to see if this trial is right for you.